Identification of Risk Factors Parkinson's Disease by Convergence Strategy (CONVERGENCE)

University Hospital, Lille

Status

Completed

Conditions

Parkinson Disease

Study type

Observational

Funder types

Other

Identifiers

NCT03536104

2008-A00219-46 (Other Identifier)

2008_0811

Details and patient eligibility

About

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Enrollment

2,220 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Inclusion criteria for Parkinson's patients and "related diseases" controls:
Parkinsonian patients meeting the Gelb criteria
Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
Woman of childbearing age having an effective means of contraception.
Informed consent signed by the subject or his legal representative.
For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.

Criteria for inclusion of non-ill controls:

Absence of rest trembling, bradykinesia and stiffness
MMSE (Mini Mental State Examination) greater than 25
Woman of childbearing age having an effective means of contraception.
subject having signed the informed consent.
No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

Exclusion criteria

Criteria for non-inclusion of patients:
Clinical criteria for exclusion of the diseases described
Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Criteria for non-inclusion of non-ill controls:

Functional discomfort in daily life of unknown cause
MMSE less than 25
Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.